Findings: Following eight weeks of NAC administration in patients with MASLD, no significant changes were observed compared to the placebo in hepatic steatosis grade ( P =0.215), serum aspartate aminotransferase (AST) ( P =0.21), alanine transaminase (ALT) ( P =0.28), malondialdehyde (MDA) ( P =0.79), total antioxidant capacity (TAC) ( P =0.56), triglycerides ( P =0.15), total cholesterol ( P =0.28), low-density lipoprotein cholesterol ( P =0.32), and high-density lipoprotein cholesterol ( P =0.16)
This can be achieved through supplementation, eating fatty fish like sardines and salmon, or a combination of the two
Whether you were on 2.5 mg or 15 mg of tirzepatide, your conversion path is mapped out below
95% CI, 1.26-1.56), but shorter duration (=26 weeks) of treatment was not (RR 0.79)